Last reviewed · How we verify

NCT04469777

Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy

Completed Phase 1, PHASE2 Last updated 1 April 2021
What this trial tests

Phase 1, PHASE2 trial testing erythropoietin in Optic Neuropathy in 20 participants. Completed in 30 December 2020.

Timeline
1 April 2019
Primary endpoint
15 December 2020
30 December 2020

Quick facts

Lead sponsorAlexandria University
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 April 2019
Primary completion15 December 2020
Estimated completion30 December 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 18 to 80, any sex, with Optic Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of erythropoietin

Trials testing the same drug.

Other recruiting trials for Optic Neuropathy

Currently open trials in the same condition.

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04469777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing